公开(公告)号：US20160320404A1

公开(公告)日：2016-11-03

申请号：US15060959

申请日：2016-03-04

申请人： Sanaria Inc. ,  Antigen Discovery, Inc. ,  The United States of America, as represented by the Secretary, Department of Health and Human

发明人： Philip FELGNER ,  Stephen L. HOFFMAN ,  Robert SEDER ,  Joseph J. CAMPO, Jr.

IPC分类号： G01N33/68 ,  A61K39/015

CPC分类号： G01N33/6854 ,  A61K39/015 ,  A61K2039/521 ,  A61K2039/522 ,  A61K2039/54 ,  G01N33/56905 ,  G01N2333/445 ,  G01N2469/20 ,  Y02A50/412 ,  Y02A50/58

摘要： Disclosed herein are diagnostic methods and compositions for identifying individuals that are protected against Plasmodium falciparum caused malaria. Such methods are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. Also disclosed herein are subunit vaccines comprising at least one Pf immunologic determinant for protection against Plasmodium-caused malaria.

摘要翻译： 本文公开了用于鉴定受疟原虫恶性疟原虫保护的个体的诊断方法和组合物。 这种方法特别有助于不仅确定Pf整个寄生虫疫苗对个体受试者的保护作用，而且还用于接种疫苗接种者的群体。 本文还公开了亚单位疫苗，其包含至少一种用于防止疟原虫引起的疟疾的Pf免疫决定簇。

公开(公告)号：US20180231566A1

公开(公告)日：2018-08-16

申请号：US15858560

申请日：2017-12-29

申请人： Sanaria Inc. ,  Antigen Discovery, Inc. ,  The United States of America, as represented by the Secretary, Department of Health and Human

发明人： Philip FELGNER ,  Stephen L. HOFFMAN ,  Robert SEDER ,  Joseph J. CAMPO, JR.

IPC分类号： G01N33/68 ,  A61K39/015 ,  G01N33/569 ,  A61K39/00

CPC分类号： G01N33/6854 ,  A61K39/015 ,  A61K2039/521 ,  A61K2039/522 ,  A61K2039/54 ,  G01N33/56905 ,  G01N2333/445 ,  G01N2469/20 ,  Y02A50/412 ,  Y02A50/58

摘要： Disclosed herein are diagnostic methods and compositions for identifying individuals that are protected against Plasmodium falciparum caused malaria. Such methods are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. Also disclosed herein are subunit vaccines comprising at least one Pf immunologic determinant for protection against Plasmodium-caused malaria.

公开(公告)号：US20160216276A1

公开(公告)日：2016-07-28

申请号：US14914869

申请日：2014-09-02

申请人： Sanaria Inc. ,  Antigen Discovery, Inc. ,  The United States of America,as represented by the Secretary, Department of Health and Human Service

发明人： Philip FELGNER ,  Stephen L. HOFFMAN ,  Robert SEDER

IPC分类号： G01N33/68 ,  A61K39/015

CPC分类号： G01N33/6854 ,  A61K39/015 ,  G01N2333/445 ,  G01N2469/20 ,  Y02A50/412 ,  Y02A50/58

摘要： Disclosed herein are diagnostic assays for identifying individuals that are protected against Plasmodium falciparum caused malaria. Such assays are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. The assays comprise the use of proteomes representing at least 50% of Pf, preferably coupled to a solid phase as a fixed array. The arrays are used to probe the sera of human subjects, particularly subjects of human clinical trials of whole parasite malaria vaccines as well as public health vaccination campaigns. Serum samples with antibody profiles most strongly reactive in multiplex to CSP and MSP5 demonstrate a sensitivity of from 92% to 100% and a specificity of from 84% to 89%.

摘要翻译： 本文公开了用于鉴定被疟原虫恶性疟原虫保护的个体的诊断测定法。 这种测定法不仅可以用于确定Pf整个寄生虫疫苗对于个体受试者的保护功效，而且还用于接种疫苗接种者的群体。 测定法包括使用表示至少50％Pf的蛋白质组，优选与固相偶联作为固定阵列。 阵列用于探测人类受试者的血清，特别是整个寄生虫疟疾疫苗的人类临床试验的受试者以及公共卫生疫苗接种运动。 具有抗CSP和MSP5多重反应的抗体谱的血清样品的灵敏度为92％至100％，特异性为84％至89％。